Scientific Publications by FDA Staff

Discov Med 2015 Nov;20(111):273-84

Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.

Joshi BH, Suzuki A, Fujisawa T, Leland P, Varrichio F, Lababidi S, Lloyd R, Kasperbauer J, Puri RK

Thyroid cancer is a rapidly increasing endocrine cancer. Since interleukin-4 receptor (IL-4R) is overexpressed in human solid cancer, we examined expression of IL-4R in 50 cases of anaplastic thyroid cancer (ATC), 37 well-differentiated papillary cancer (WDPC), 35 well-differentiated follicular cancer of thyroid (WDFC), and 37 normal thyroid specimens by immunohistochemistry (IHC) and in-situ hybridization (ISH) techniques. We demonstrated that IL-4Ra was overexpressed in 36/50 (72%) ATC, 20/35 (57%) WDFC, and 11/37 (30%) WDPC tumors. Other two subunits of IL-4R, interleukin-13 receptor a1 (IL-13Ra1) and interleukin-2 receptor gamma (IL-2R¿C), were either weakly expressed or absent. As ATC is a highly aggressive cancer with higher incidence of IL-4Ra expression, we characterized IL-4R in 3 ATC cell lines. RT-qPCR and IFA results showed that IL-4Ra is overexpressed while IL-13Ra1 is weakly expressed. Control human umbilical vein endothelial cell line (HUVEC) showed weak expression of IL-4Ra. Binding and competition studies with 125I-IL-4 in ATC cell lines demonstrated that IL-4 specifically bound to IL-4Ra on cell surface. ATC cell lines were highly sensitive to a chimeric fusion cytotoxin consisting of circularly permuted IL-4 and truncated Pseudomonas exotoxin (IL-4-PE), which killed them in a concentration dependent manner. IL-4-PE also blocked colony formation of ATC cell lines in clonogenic assays. IL-4-PE mediated a significant antitumor activity in mouse models of ATC. Intratumoral administration of IL-4-PE caused significant regression of established tumors in a dose dependent manner and increased the overall survival without any visible toxicity. Thus, IL-4Ra in ATC may represent a novel therapeutic target and IL-4-PE may serve as an investigational therapeutic option for ATC.